Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Fosun Pharma’s $600 Million Hong Kong IPO: Is it a Steal?

publication date: Oct 12, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Fosun Pharmaceutical’s $600 million Hong Kong IPO is being marketed to potential investors as a value play, a way of investing in a large portfolio of China pharma companies at a discount. Here’s the pitch: Fosun owns 32% of China’s largest drug distributor, Sinopharm, a stake that is worth $2.6 billion. That equals 80% of Fosun’s total market capitalization – currently $3.3 billion. For a relatively small $600 million in value over and above Sinopharm, investors get Fosun’s drug production business and its stakes in a variety of China pharma companies. That, say the investment bankers, means investors are getting a discounted deal. More details....

Stock Symbols: (SHA 600196) (HK: 1099)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...